Business
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. As previously reported, on October 1, 2025, Azitra received a letter from the NYSE America
About this update from Azitra Inc
[{"type":"text","content":"BRANFORD, Conn., Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. As previously reported, on October 1, 2025, Azitra received a letter from the NYSE American stating that Azitra is not in compliance with the minimum stockholders' equity requirement of Section 1003(a)(ii) of the Company Guide requiring stockholders' equity of $4.0 million or more if Azitra has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years.","length":896,"tagName":"p"},{"type":"image","alt":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","displaySize":"","headline":null,"caption":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":199,"url":"https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ADn6KpXSrfB9stFJaBf9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199}},"href":"https://mma.prnewswire.com/media/2555910/Azitra_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Azitra must regain compliance with the continued listing standards by April 1, 2027. If Azitra is not in compliance with the continued listing standards by April 1, 2027, or if Azitra does not make progress consistent with the Plan during the plan period, NYSE Regulation staff will initiate delisting proceedings as appropriate.","length":329,"tagName":"p"},{"type":"text","content":"Azitra will continue its listing on NYSE American during the plan period and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan until it has regained compliance. Azitra is assessing and exploring multiple funding avenues and is committed to achieving compliance with the Exchange's requirements.","length":345,"tagName":"p"},{"type"...